


## **Study on Molecular basis of Cancer induced angiogenesis**

**ABSTRACT:** Cancer is a disease caused by defective cells that have an uncontrollable ability to proliferate without regard for the physiological organ. Cancer is a complicated multi-factorial, multi-staged, and multi-mechanistic disease. Within the initiation and course of manifestation, it comprises the interaction of environmental and host elements. Inherited genetic dispositions have a significant role in 5-10% of breast cancer cases and 5- 13% of colon cancer cases. Viral infections cause about 7% of cancer fatalities in developed countries; 4% are due to occupational hazards; 2% are due to sunlight; 2% are due to pollution of air, water, and soil; and less than 1% are due to food components and business products.

**Keywords:** Etiology, Epidemiology, Cancer, Angiogenesis, MMP, Hypoxia.

**INTRODUCTION:** When fed persistently, several chemical and physical cancer agents can cause one or more of a variety of mutations in cells [1]. A desired array of cancer-causing chemical substances is man-made, pesticides, pharmaceutical chemicals, or food additives [2]. Carcinogens are a broad category that includes both natural and manmade products [3]. Surprisingly, all chemical carcinogens are electrophiles that combine with electron-rich atoms like RNA, DNA and protein [4]. Lung and prostate cancers can be improved by metals such as arsenic and arsenic compounds, chromium, nickel, cadmium, and beryllium [5]. Physical carcinogens, such as X-rays and UV rays, can cause the development of pyrimidine dimers and apurinic web sites in DNA, as well as the generation of free radicals, which cause DNA damage and somatic mutations [6]. In animals, a large variety of DNA and RNA viruses have been found to be carcinogenic, but only a few viruses have been linked to human cancer [7]. Metastasis is the most life-threatening feature of the oncogenic process [8]. Even although the clinical significance of such expression of the malignant phenotype has been well appreciated, advances in know-how the molecular mechanisms involved in metastasis have lagged in the back of different trends within the cancer subject [Figure 1] [9].



**Figure 1:** Tumors induce blood vessel growth in promoting angiogenesis, Image courtesy of the National Cancer Institute, Cancer Information and Support Network.

**MATRIX METALLOPROTEINASES:** MMPs (matrix metalloproteinases) are a group of zinc metallo endopeptidases that have a role in the turnover of extracellular matrix components [10]. These enzymes are involved in various disorders such as arthritis, cancer, periodontitis, glomerulonephritis, encephalomyelitis, atherosclerosis, and tissue ulceration, as well as normal embryogenesis and tissue remodelling [11]. The main physiologic inhibitors of MMPs are tissue inhibitors of metalloproteinases (TIMPs) [12]. TIMPS are secreted proteins that form complexes with human MMPs and regulate their activity [13]. MMPs and TIMPs form a sophisticated organic device that tightly controls extracellular matrix breakdown [14]. MMPs and TIMPs play a large role in tumour invasion and metastasis, not only through their direct role in degrading extracellular matrix, but also through interactions with other biological structures involved in tumour invasion, such as cell adhesion molecules, cytoskeletal proteins, and boom elements [15].

**TIMP-1 AND 2:** TIMP-1 mRNA expression is up-regulated in a variety of human cancers and is associated with a worse clinical outcome in a few cases, such as colorectal carcinoma, non-small cell lung carcinoma, and breast carcinoma [16]. TIMP-1 has been shown to have proneoplastic and antineoplastic effects at various stages in the progression of primary and metastatic tumours in experimental mice models [17]. TIMP-2 is a multifunctional angiogenesis, tumour growth, and tumour invasion inhibitor [18]. These methods entail not only the manipulation of tumour cells, but also the manipulation of intricate tumor-host relationships [19]. Because the host response to the tumour microenvironment can help or hinder tumour invasion and dissemination, regulating those host reaction aspects has been a


major focus of new anticancer research [20]. TIMP-2 can impede MMPs' activities, but it can also rely on MMP-independent pathways to control tumor-host interactions [21]. TIMP-2 plays an immediate role in modulating the activation of tyrosine kinase-type growth issue receptors [22].

**ANGIOGENESIS:** Angiogenesis, or the generation of new capillaries, is a fundamental event in a variety of harmful pathologic processes, such as tumour growth, metastasis, arthritis, and so on, as well as physiologic processes like as organ growth and development, wound healing, and reproduction [23]. Blood vessels are the embryo's first organ and the body's largest network, but they're also the most dangerous [24]. The development of new blood vessels contributes to severe neoplastic, ischemic, inflammatory, infectious, and immunological illnesses when it is dysregulated [25]. Molecular insights into these procedures are being developed at an unexpectedly fast rate, resulting in new treatment possibilities that are currently being investigated [26].

**TUMOR GROWTH AND METASTASIS:** Angiogenesis is required for invasive tumour growth and metastasis, and it is a critical component of cancer management [27]. Tumors must perform an angiogenic flip by disrupting the local stability of proangiogenic and antiangiogenic factors in order to broaden in length and reach metastatic potential [28]. Increased levels of proangiogenic proteins, such as vascular endothelial growth factor (VEGF) and simple fibroblast boom factor (bFGF), are typically found in neovascularized tumours [29]. Many factors can trigger the production of proangiogenic proteins, including hypoxia, oncogene activation, and tumour suppressor gene inactivation [30]. Antiangiogenic components are downregulated in some cancers, resulting in angiogenic transfer [31]. The stability of proangiogenic and antiangiogenic signals favours vasculature in most mature tissues [32]. However, in some cases, proangiogenic activities win out, resulting in tumour vascularization and metastatic spread [33]. In the creation of antiangiogenic agents, two general strategies have been used: inhibition of proangiogenic problem and therapy with endogenous angiogenesis inhibitors [34].


**VASCULAR ENDOTHELIAL GROWTH ELEMENT:** Cancer and stromal cells, the extracellular matrix (ECM), and the vasculature are the three primary compartments in solid tumours [35]. The volumes of these components differ depending on the tumor's foundation and length, as well as the organ in which the main tumour originates [36]. Tumors require

vasculature to gain access to oxygen and other nutrients, allowing them to grow and spread [37]. One of the most potent angiogenic agents produced by tumour cells has been identified as VEGF (vascular endothelial growth factor) [38]. It binds to endothelial cell surface receptors and activates a variety of mobile activities, including angiogenesis [39] Figure 2 [42].



**Figure 2:** Role of MMPs in tumor growth and progression to angiogenesis [43].

**ROLE OF HYPOXIA:** After a certain distance, simple oxygen transport to metabolising tissues becomes insufficient [44]. To fulfil the demands of the expanding quantity of cells, the increased rate of cell division in cancer involves metabolic pathways. [45]. Many cancers create a dangerously hypoxic milieu and release angiogenesis-stimulating factors such as platelet-derived growth factor (PDGF) and VEGF [46]. VEGF expression is increased in tumour zones around necrotic foci, suggesting a mechanism through which a hypoxic microenvironment can promote tumour angiogenesis [47]. The hypoxia-inducible factor (HIF) gene family, which codes for heterodimeric fundamental helix-loop-helix proteins made up of  $\alpha$  and  $\beta$  subunits, is activated. HIF-1 $\alpha$ : is synthesised in the cytoplasm of cells but rapidly destroyed under normoxia; nevertheless, after a decrease in oxygen anxiety, the intracellular concentration of HIF-1 increases immediately [48]. HIF-1 is a transcription factor that mediates hypoxia-induced reactions [Figure 3], including apoptosis and the expression of the VEGF gene [49]. As a result, the availability of oxygen is a critical regulator of tumour angiogenesis [50].




**Figure 3:** Role of hypoxia in cancer, Image adopted from Trends in Cancer; Rankin EB *et.al*, 2016 [50].

**T-LYMPHOCYTES:** In the host, CTLs provide efficient anticancer immunity. CTLs can also perform a surveillance function by identifying and eliminating potentially malignant cells that express peptides derived from mutant mobile or oncogenic viral proteins that are displayed in conjunction with class I MHC molecules [51]. The role of NK cells and macrophages NK cells can be triggered by direct tumour identification or by cytokines released by tumor-specific T lymphocytes [52]. The ability of NK cells to recognise tumour cells is not limited by MCH [53]. Fc receptors on NK cells can connect to antibody-covered tumour cells in some situations, resulting in antibody dependent mobile cytotoxicity (ADCC) [54]. Activated macrophages play a key role in immune responses to malignancies by releasing lysosomal enzymes or reactive oxygen metabolites. [55]. Macrophages also have Fc receptors, which allows them to mediate ADCC [56]. TNF- $\alpha$  is produced by activated macrophages and has anticancer properties [57]. Immune Surveillance and the Role of Immune Devices in Tumor Improvement Host allows for both humoral and cellular immune responses to tumour antigens, and has been shown to be effective in tumour immune elimination [58]. CTLs (cytotoxic T lymphocytes) with tumor-specific characteristics have been found in a variety of malignancies

[59]. Natural killer cells, macrophages, and tumor-specific antibodies are all important effectors [60]. CTLs (cytotoxic T lymphocytes) produce potent anti-tumor immunity in the host [61]. CTLs can also undertake surveillance by detecting and destroying potentially cancerous cells that include peptides derived from mutant cell or oncogenic viral proteins that are expressed in combination with class I MHC molecules [62].

**ROLE OF NK CELLS AND MACROPHAGES:** NK cells can be triggered either by tumour direct popularity or by cytokines generated by tumor-specific T-lymphocytes [63]. MCH isn't required for NK cells to recognise tumour cells [64]. Fc receptors on NK cells can attach to antibody-coated tumour cells in some cases, resulting in antibody-based cellular cytotoxicity [65]. Activated macrophages may also play a role in immunological responses to malignancies by releasing lysosomal enzymes, reactive oxygen metabolites, or generating TNF- $\alpha$ , according to numerous observations [66]. Macrophages have Fc receptors that allow them to mediate ADCC [67]. TNF- $\alpha$  is produced by activated macrophages and has anticancer properties [68].

**ADCC:** Antibody Dependent Cell Cytotoxicity (ADCC) is a technique in which tumour cells that have been coated with IgG antibodies are selectively destroyed by killer cells, a type of lymphomonocytic cytotoxicity [69]. Several distinct leukocyte populations, including neutrophils, eosinophils, mononuclear phagocytes, and natural killer cells (NK cells), are capable of lysing target cells [70]. Fc $\gamma$ RIII, also known as CD16, is a low affinity Fc $\gamma$  receptor on the leukocyte that recognises certain antibodies [71]. The antibody molecule sends out a specific popularity signal, whilst the nonspecific effector cells are directed to the target cells to deliver the cytotoxic impact [72].



**Figure 4:** Role of immune cells in promotion and inhibition of cancer, Image adopted from Le QV et.al., 2019 [73].

**TUMOR ESCAPE MECHANISM:** Although immunosurveillance may limit the outgrowth of some malignancies [Figure 4], it is clear that the immunological gadget rarely saves the incidence of human fatal cancers [73]. It could be because a tumor's rapid development and dissemination overwhelms the immune system's effector mechanisms [74]. The host's inability to expand an efficient immune response has also been demonstrated in numerous classes [75]. The way a tumour spreads can be caused by a variety of causes, as listed below [76]. A) Tumor cells can have their Class I MHC expression reduced, which is essential for CTL identification [77]. B) Tumor products (e.g., TGF- $\beta$ ) may decrease antitumor immune responses [78, 79]. C) Loss of tumour antigen expression [80]. D) Antigens on the surface of tumours can be masked from the immune system [81].

**CYTOKINES:** Small secreted proteins called cytokines mediate and control immunity, infection, and hematopoiesis [82]. They are tiny structural proteins that range in molecular weight from 8 to 40 KD [83]. They work by attaching to specific membrane receptors, which then sign the cells via second messengers, such as tyrosine kinases, to control its behaviour (gene expression) [84]. Growing or decreasing the expression of membrane proteins (together with cytokine receptors), proliferation, and release of effector molecules are all responses to cytokines [85]. Endogenous immunostimulatory proteins are known as cytokines [86].

Cytokines are important players in tumour metastasis [87]. Some cytokines may also reduce tumour growth by interfering with host tumour dating, for example, by reducing tumour angiogenesis and modulating the larger cellular matrix [88].

**CONCLUSION:** Apoptosis, rather than necrosis, is the most common mode of physiological cellular death. Abnormalities in this approach have been linked to a range of diseases as a cause or contributing factor. Inhibition of apoptosis can accelerate neoplastic transformation, especially when combined with a disrupted cellular cycle, and may affect tumour cells' response to anti-cancer therapy. Caspase regulators, including activators and inhibitors of mobile loss of life proteases, have also been discovered. In multicellular organisms, it is a key procedure for maintaining tissue homeostasis. Apoptosis may be caused with the aid of a variety of stimuli together with ionizing radiations, gluco-corticoids chemotherapeutic dealers, lymphokines deprivation and diverse oxidants. Although the stimuli which set off apoptosis range markedly, the morphological functions of the manner are but conserved in special mobile sorts. It includes chromatin condensation, nuclear fragmentation, Plasma membrane blebbing, mobile shrinkage and formation of apoptotic bodies.

## **REFERENCES:**

1. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proceedings of the National Academy of Sciences. 2003;100(3):776-81.
2. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent patents on inflammation & allergy drug discovery. 2009;3(1):73-80.
3. Belpomme D, Irigaray P, Hardell L, Clapp R, Montagnier L, Epstein S, Saso AJ. The multitude and diversity of environmental carcinogens. Environmental research. 2007;105(3):414-29.
4. Groeger AL, Freeman BA. Signaling actions of electrophiles: anti-inflammatory therapeutic candidates. Molecular interventions. 2010;10(1):39.
5. Verougstraete V, Lison D, Hotz P. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. Journal of Toxicology and Environmental Health, Part B. 2003;6(3):227-56.

6. Dahlmann HA, Vaidyanathan VG, Sturla SJ. Investigating the biochemical impact of DNA damage with structure-based probes: abasic sites, photodimers, alkylation adducts, and oxidative lesions. *Biochemistry*. 2009;48(40):9347-59.
7. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. *Carcinogenesis*. 2000;21(3):405-26.
8. Vemuri PK, Nimmagadda G, Bodiga S, Bodiga VL, Veeravilli S, Rao KS. Immune surveillance of tumor milieu during angiogenesis. *Int. J. Life Sci. Pharma Res*. 2021;11(1):102-6.
9. Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. *Genes & development*. 2018;32(13-14):868-902.
10. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. *The journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland*. 2003;200(4):448-64.
11. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. *Trends in molecular medicine*. 2007;13(11):449-59.
12. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. *Clinical cancer research*. 2004;10(24):8229-34.
13. Karalaki M, Fili S, Philippou A, Koutsilieris M. Muscle regeneration: cellular and molecular events. *In vivo*. 2009;23(5):779-96.
14. Rathna R, Madhumitha B, Viveka R, Nakkeeran E. Recent Insights of Matrix Metalloproteinase Inhibitors in Therapeutic Applications. *Enzyme Inhibition-Environmental and Biomedical Applications*. 2020;1:73-96.
15. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland*. 2003;201(4):528-34.

16. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, Rees RC. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. *The Journal of Immunology*. 1997;158(5):2327-33.
17. Adachi Y, Nojima M, Mori M, Yamashita K, Yamano H, Endo T, Kato Y, Nakase H, Imai K, Sakata K, Tamakoshi A. Tumor Marker Publication. *Tumor Biology*. 2017;1:21.
18. Eble JA, Niland S. The extracellular matrix of blood vessels. *Current pharmaceutical design*. 2009;15(12):1385-400.
19. Xu T, Yu S, Zhang J, Wu S. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. *Journal of hematology & oncology*. 2021;14(1):1-20.
20. Feldman AL, Stetler-Stevenson WG, Costouros NG, Knezevic V, Baibakov G, Alexander HR, Lorang D, Hewitt SM, Seo DW, Miller MS, O'Connor S. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. *Cancer research*. 2004;64(13):4481-6.
21. Shishir TA, Khan RI, Nirzhor SS. The critical role of tumor microenvironment in cancer evolution and metastasis. *Int. J. Bus. Res*. 2018;9:244-58.
22. Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. *Trends in molecular medicine*. 2005;11(3):97-103.
23. Wesolowski SR, Allan MF, Nielsen MK, Pomp D. Evaluation of hypothalamic gene expression in mice divergently selected for heat loss. *Physiological genomics*. 2003;13(2):129-37.
24. Carmeliet P. Angiogenesis in health and disease. *Nature medicine*. 2003;9(6):653-60.
25. Tecklenborg J, Clayton D, Siebert S, Coley SM. The role of the immune system in kidney disease. *Clinical & Experimental Immunology*. 2018;192(2):142-50.
26. Modi U, Makwana P, Vasita R. Molecular insights of metastasis and cancer progression derived using 3D cancer spheroid co-culture in vitro platform. *Critical reviews in oncology/hematology*. 2021;168:103511.

27. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. *Nature reviews Drug discovery*. 2010;9(7):537-50.
28. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. *Nature medicine*. 2011;17(11):1359-70.
29. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). *The American journal of pathology*. 2006;169(5):1875-85.
30. Grazul-Bilska AT, Johnson ML, Bilski JJ, Redmer DA, Reynolds LP, Abdullah A, Abdullah KM. Wound healing: the role of growth factors. *Drugs Today (Barc)*. 2003;39(10):787-800.
31. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. *Current opinion in genetics & development*. 2001;11(3):293-9.
32. Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, Ataei F, Dana N, Javan M. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1 $\alpha$ /VEGF signaling axis in breast cancer cells. *Cellular oncology*. 2017;40(5):457-70.
33. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. *Cancer letters*. 2008 Aug 28;267(2):204-15.
34. Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, LaValley MP, Hamburg NM, Vita JA, Hess DT. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. *Circulation*. 2014;130(13):1072-80.
35. Kumar VP, Prasanthi S, Lakshmi VR, Santosh MS. Cancer vaccines: a promising role in cancer therapy. *Acad J Cancer Res*. 2010;3(2):16-21.
36. Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. *Human genomics*. 2015;9(1):1-8.
37. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH. Artificial intelligence in cancer imaging: clinical challenges and applications. *CA: a cancer journal for clinicians*. 2019;69(2):127-57.

38. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. *Nature clinical practice Oncology*. 2007;4(9):536-50.
39. Borre M, Nerstrøm B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. *Clinical Cancer Research*. 2000;6(5):1882-90.
40. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. *Glycobiology*. 2014;24(10):886-91.
41. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clinical science*. 2005;109(3):227-41.
42. Hoeben AN, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. *Pharmacological reviews*. 2004;56(4):549-80.
43. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. *Pathology oncology research*. 2001;7(1):14-23.
44. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, van Gool R. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. *Cancer research*. 2009;69(4):1517-26.
45. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. *Gynecologic oncology*. 2011;121(1):181-6.
46. Rajabi S, Dehghan MH, Dastmalchi R, Mashayekhi FJ, Salami S, Hedayati M. The roles and role-players in thyroid cancer angiogenesis. *Endocrine journal*. 2019;66(4):277-93.
47. Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX. Angiogenesis in pancreatic cancer: current research status and clinical implications. *Angiogenesis*. 2019;22(1):15-36.

48. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. *Laboratory investigation*. 2004;84(4):397-405.
49. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. *The Journal of clinical investigation*. 2013 Sep 3;123(9):3664-71.
50. Rankin EB, Nam JM, Giaccia AJ. Hypoxia: signaling the metastatic cascade. *Trends in cancer*. 2016;2(6):295-304.
51. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nature medicine*. 2003;9(6):677-84.
52. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *cell*. 2011;144(5):646-74.
53. Qin M, Wang D, Fang Y, Zheng Z, Liu X, Wu F, Wang L, Li X, Hui B, Ma S, Tang W. Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. *Frontiers in Oncology*. 2021;11.
54. Senthil P, Balakrishnan H. The Engineering of Natural Killer Cells as an Emerging Adoptive Cancer Immunotherapy. *Journal of Young Investigators*. 2020;38(5).
55. Nishikawa M. Reactive oxygen species in tumor metastasis. *Cancer letters*. 2008;266(1):53-9.
56. Al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. *Journal of the Royal College of Surgeons of Edinburgh*. 2000;45(1).
57. Gordan S, Biburger M, Nimmerjahn F. bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. *Immunological reviews*. 2015;268(1):52-65.
58. Schirmacher V, Bai L, Umansky V, Yu LI, Xing YO, Qian ZH. Newcastle disease virus activates macrophages for anti-tumor activity. *International journal of oncology*. 2000;16(2):363-436.

59. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. *Molecular cancer*. 2011;10(1):1-2.
60. Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. *Trends in immunology*. 2019;40(2):142-58.
61. Lull C, Wichers HJ, Savelkoul HF. Antiinflammatory and immunomodulating properties of fungal metabolites. *Mediators of inflammation*. 2005(2):63-80.
62. Rodriguez GM, Bobbala D, Serrano D, Mayhue M, Champagne A, Saucier C, Steimle V, Kufer TA, Menendez A, Ramanathan S, Ilangumaran S. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8<sup>+</sup> T lymphocytes. *Oncoimmunology*. 2016;5(6):e1151593.
63. Shoshan SH, Admon A. MHC-bound antigens and proteomics for novel target discovery. *Pharmacogenomics*. 2004;5(7):845-59.
64. Zeng G. MHC class II-restricted tumor antigens recognized by CD4<sup>+</sup> T cells: New strategies for cancer vaccine design. *Journal of Immunotherapy*. 2001;24(3):195-204.
65. Erdei A, Sándor N, Mácsik-Valent B, Lukácsi S, Kremlitzka M, Bajtay Z. The versatile functions of complement C3-derived ligands. *Immunological reviews*. 2016;274(1):127-40.
66. Wagner AK, Alici E, Lowdell MW. Characterization of human natural killer cells for therapeutic use. *Cytotherapy*. 2019;21(3):315-26.
67. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. *Frontiers in physiology*. 2014;5:352.
68. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. *The Journal of Immunology*. 2011;186(2):1022-31.
69. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nature Reviews Immunology*. 2010;10(5):317-27.

70. Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. *Experimental hematology*. 2008;36(1):69-77.
71. Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. *The Journal of Immunology*. 1994;153(3):1254-63.
72. Sulica A, Morel R, Metes D, Herberman RB. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. *International reviews of immunology*. 2001;20(3-4):371-414.
73. Le QV, Yang G, Wu Y, Jang HW, Shokouhimehr M, Oh YK. Nanomaterials for modulating innate immune cells in cancer immunotherapy. *Asian journal of pharmaceutical sciences*. 2019;14(1):16-29.
74. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. *Immunity*. 2013;39(1):74-88.
75. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology*. 2014;143(4):512-9.
76. Gellatly SL, Hancock RE. *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. *Pathogens and disease*. 2013;67(3):159-73.
77. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *cell*. 2011;144(1):27-40.
78. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. *Journal of cellular physiology*. 2003;195(3):346-55.
79. Mulligan JK, Young MR. Tumors induce the formation of suppressor endothelial cells in vivo. *Cancer immunology, immunotherapy*. 2010 Feb 1;59(2):267.
80. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. *Nature*. 2012;482(7385):405-9.

81. Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. *Immunological reviews*. 2017;280(1):165-74.
82. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. *Frontiers in immunology*. 2014;5:491.
83. Zhao JL, Ma C, O'Connell RM, Mehta A, DiLoreto R, Heath JR, Baltimore D. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. *Cell stem cell*. 2014;14(4):445-59.
84. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. *Expert opinion on drug delivery*. 2008;5(4):371-83.
85. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nature Reviews Neuroscience*. 2003;4(4):299-309.
86. Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. *Journal of Photochemistry and Photobiology B: Biology*. 2009;96(1):1-8.
87. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. *The Journal of Immunology*. 2002;168(12):5989-92.
88. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone?. *Cancer and Metastasis Reviews*. 2008;27(1):41-55.
89. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. *Pharmacological reviews*. 2000;52(2):237-68.